JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Intellia Therapeutics Reports Promising Phase 1 Trial Results for Nexiguran Ziclumeran in ATTR Amyloidosis
Express News | Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-Z), an in Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (Attr) Amyloidosis
Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $90
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday